SUBSCRIBE TO OUR RSS
INITIAL PUBLIC OFFERINGS
An Open Window
Life Sciences companies that have gone public since August 2009.
The Burrill Report
April 08, 2010
[Please login to post comments]
The Rise in Drug Spending and What It Means
Podcast: April 21, 2014
HHS Secretary Sebelius Resigns
Biotech IPOs Cool Amid Market Jitters
As public market enthusiasm wavers, companies going public face tougher terms.
Mallinckrodt To Buy Questcor for $5.6 Billion
Deal adds high-value specialty drug to pharma’s growing pipeline.
Study Highlights Opportunities to Reduce Spending on Costly Specialty Drugs
New report says payers could benefit by transitioning specialty medications from the medical to the pharmacy benefit.
Personalizing Cancer Therapies with a Mouse
Podcast: April 14, 2014
Intarcia Lands $200M for Disruptive Drug Delivery
Financing will fund push to get its once-yearly diabetes medication on the market.
AbbVie Drops Attempt to Block EU Clinical Trial Transparency Effort
Pharma says European regulators accepted its rationale to protect certain information.
Forma Therapeutics and Celgene Form $600M Alliance
Biotech gets a big cash payment and an exit opportunity for its backers.
Stem Cells Improve Heart Function
Danish study shows stem cells are effective for failing hearts.
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER